To include your compound in the COVID-19 Resource Center, submit it here.

Voyager gains on additional PD gene therapy data

Voyager Therapeutics Inc. (NASDAQ:VYGR) climbed $2.70 (25%) to $13.63 on Wednesday after updated data from a Phase Ib trial showed that Parkinson’s disease candidate VY-AADC01 led to durable, dose-dependent improvements across multiple measures of motor function. Next half, the

Read the full 392 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE